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Abstract 
Background: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a once‑
daily, single‑tablet regimen for treatment of HIV‑1 infection. The efficacy/safety of switching to D/C/F/TAF versus con‑
tinuing boosted protease inhibitor (bPI) + emtricitabine/tenofovir disoproxil fumarate (control) were demonstrated in 
a phase 3, randomized study (EMERALD) of treatment‑experienced, virologically suppressed adults through week 48.  
The objective of this analysis was to evaluate EMERALD outcomes across subgroups of patients based on demo‑
graphic characteristics, prior treatment experience, and baseline antiretroviral regimen.
Methods: EMERALD patients were virologically suppressed (viral load [VL] < 50 copies/mL for ≥ 2 months at screen‑
ing). Prior non‑darunavir virologic failure (VF) was allowed. Primary endpoint was proportion of patients with virologic 
rebound (confirmed VL ≥ 50 copies/mL) cumulative through week 48. Virologic response was VL < 50 copies/mL (FDA 
snapshot). Safety was assessed by adverse events, renal proteinuria markers, and bone mineral density. Outcomes 
were examined for prespecified subgroups by age (≤/> 50 years), gender, race (black/non‑black), prior number of 
antiretrovirals used (4/5/6/7/> 7), prior VF (0/≥ 1), baseline bPI (darunavir/atazanavir or lopinavir), and baseline boost‑
ing agent (ritonavir/cobicistat).
Results: Among 1141 patients in the D/C/F/TAF (n = 763) and control (n = 378) arms, virologic rebound rates (2.5% 
and 2.1%, respectively) were similar, and this was consistent across all subgroups. Virologic response rates ranged from 
91 to 97% (D/C/F/TAF) and 89 to 99% (control) across all subgroups, with differences between treatment arms of  
0 and 6%. Adverse event rates were low in both arms and across subgroups. Improvements in renal and bone param‑
eters were observed with D/C/F/TAF across demographic subgroups.
Conclusions: For treatment‑experienced, virologically suppressed patients, switching to D/C/F/TAF was highly effec‑
tive and safe, regardless of demographic characteristics, prior treatment experience, or pre‑switch bPI.
Trial registration ClinicalTrials.gov Identifier: NCT02269917. Registered 21 October 2014. https ://clini caltr ials.gov/ct2/
show/NCT02 26991 7
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Background
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide 
(D/C/F/TAF) 800/150/200/10  mg is an oral, once-daily 
(QD) single-tablet regimen (STR) for the treatment of 
human immunodeficiency virus (HIV)-1 infection. The 
darunavir component has demonstrated efficacy and 
safety, as well as a high barrier to resistance [1, 2]. A daru-
navir-based regimen is recommended in guidelines from 
the European AIDS Clinical Society, and the US Depart-
ment of Health and Human Services recommends a daru-
navir-based regimen in clinical situations such as when 
there are adherence concerns or resistance data are not 
available prior to treatment initiation (i.e., when a high 
barrier to resistance is important) [3, 4].
In the phase 3 EMERALD study, treatment-expe-
rienced, virologically suppressed adults switched to 
D/C/F/TAF or remained on a boosted protease inhibi-
tor (bPI) + emtricitabine/tenofovir disoproxil fumarate 
(TDF) regimen; D/C/F/TAF was noninferior versus the 
control regimen (4% margin) for cumulative virologic 
rebound through week 48 [5]. High virologic response 
rates and a favorable safety profile were also shown for 
D/C/F/TAF. Notably, EMERALD had less strict enroll-
ment criteria for treatment experience compared with 
other recent switch studies, allowing a broader range of 
patients that may be more representative of patients who 
require a switch in clinical practice [6–8]. Specifically, 
patients with prior experience with multiple antiretrovi-
rals (ARVs) and/or prior virologic failure (VF) and those 
with an HIV-1 RNA blip prior to screening were eligible 
to enroll, and there were no restrictions on emtricitabine 
or tenofovir resistance-associated mutations (RAMs). To 
examine the efficacy and safety of D/C/F/TAF in specific 
populations of patients who may switch to this regimen, 
we evaluated results from EMERALD across subgroups 
of patients based on demographic characteristics, prior 
treatment experience, and ARV regimen used at baseline.
Methods
Study design
EMERALD was a phase 3, randomized, active-con-
trolled, multicenter, open-label trial evaluating efficacy, 
resistance development, and safety in treatment-expe-
rienced, virologically suppressed patients with HIV-1 
who switched from a bPI + emtricitabine/TDF regimen 
to D/C/F/TAF, or continued on their current regimen. 
The bPI was darunavir or atazanavir (with ritonavir or 
cobicistat) or lopinavir (with ritonavir). Detailed study 
methods for EMERALD have previously been described 
[5].
Analyses
Efficacy was assessed by the proportion of patients 
with cumulative virologic rebound (confirmed HIV-1 
RNA ≥ 50 copies/mL) through week 48 (primary end-
point) and virologic response (HIV-1 RNA < 50  copies/
mL) and VF at week 48 (US Food and Drug Adminis-
tration [FDA] snapshot approach) [9]. The difference 
(95% confidence interval [CI]) between the D/C/F/TAF 
and control arms for virologic rebound and virologic 
response for subgroups was calculated using exact CIs. 
The trial was not powered for statistical testing of treat-
ment-by-subgroup interaction.
To evaluate post-baseline resistance, genotyping was 
performed in patients with virologic rebound who also 
had a viral load measurement of ≥ 400 copies/mL at the 
time of VF, at later time points, or at discontinuation.
Safety was assessed by monitoring adverse events 
(AEs). For subgroups based on demographic character-
istics, additional safety analyses are reported (renal and 
lipid laboratory parameters, and, for patients in the bone 
investigation substudy, changes in bone mineral density 
[BMD]).
Prespecified subgroup analyses were performed on 
all randomized patients who received ≥ 1 dose of study 
drug. Demographic subgroups were based on age (≤ 50 
vs > 50  years), gender (men vs women), and race (non-
black/African American vs black/African American). 
Prior treatment experience subgroups were based on 
the number of prior ARVs used (including those used 
at baseline; 4 vs 5 vs 6 vs 7 vs > 7 prior ARVs used) and 
prior VF (0 vs ≥ 1 prior VF). Subgroups corresponding to 
ARV regimen at baseline were based on bPI (darunavir 
[with ritonavir or cobicistat] vs atazanavir [with ritonavir 
or cobicistat] or lopinavir [with ritonavir]) and boosting 
agent (ritonavir [with darunavir, atazanavir, or lopinavir] 
vs cobicistat [with darunavir or atazanavir]).
Additionally, because polypharmacy may be a con-
cern among older individuals, age subgroups (≤ 50 
vs > 50 years) were further divided for assessment based 
on the presence or absence of polypharmacy (defined 
as ≥ 5 [non-ARV] concomitant medications at baseline).
Keywords: HIV‑1, Darunavir, Antiretroviral, Protease inhibitor, Single‑tablet regimen, Switch study
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Results
Study population
A total of 1141 patients were randomized and treated in 
EMERALD, including 763 in the D/C/F/TAF arm and 
378 in the control arm. Baseline demographics, clini-
cal characteristics, and prior ARV use were generally 
balanced in both treatment arms (see Additional file  1: 
Table  S1). Prior to their ARV regimen at screening, 
41% of all patients had used ≥ 1 other PI, 42% had 
used ≥ 1 other nucleos(t)ide reverse transcriptase inhibi-
tor, and 30% had used ≥ 1 nonnucleoside reverse tran-
scriptase inhibitor.
Efficacy
Cumulative virologic rebound rates were low in the 
D/C/F/TAF and control arms and similar across all 
subgroups evaluated, ranging from 0.0 to 7.2% with 
D/C/F/TAF and 0.0 to 3.3% with control (Fig.  1). Con-
sistent with these results, virologic response rates were 
high in the D/C/F/TAF and control arms and simi-
lar across all subgroups, ranging from 91 to 97% with 
D/C/F/TAF and 89 to 99% with control (Fig. 2). Cumu-
lative virologic rebound rates and virologic response 
rates for patients ≤ 50  years without polypharmacy and 
patients > 50  years with polypharmacy also fell within 
these ranges. Together, these study results suggest that 
the efficacy of D/C/F/TAF was not impacted by patients’ 
demographic characteristics, prior treatment experience, 
or ARV regimen at the time of treatment switch.
Resistance
Four patients who rebounded had post-baseline geno-
types available; 1 patient (D/C/F/TAF arm) had used 
8 prior ARVs, 1 patient (control arm) had used 6 prior 
ARVs, and 2 patients (control arm) had used 4 prior 
ARVs. None of these 4 patients had a history of prior 
VF. No darunavir, primary PI, emtricitabine, or tenofovir 
RAMs were observed in these patients or any arm across 
subgroups [5].
Safety
The incidence of AEs was similar in the D/C/F/TAF and 
control arms across all subgroups, except for a numeri-
cally higher incidence of study drug-related AEs with 
D/C/F/TAF relative to control (Table  1 and see Addi-
tional file 1: Tables S2 and S3). Rates of discontinuation 
due to AEs and rates of serious AEs were low with both 
D/C/F/TAF and control across subgroups, regardless 
of relatedness to study drug (in the overall population, 
1% of patients in each arm discontinued due to AEs and 
5% of patients in each arm had a serious AE [5]). The 
most common study drug-related AEs (≥ 2% in either 
arm) were diarrhea (D/C/F/TAF, 2%; control, 1%) and 
osteopenia (D/C/F/TAF, 1%; control, 2%) [5].
Across subgroups based on age, gender, and race, 
mean changes in markers of proteinuria from baseline to 
week 48 generally decreased in the D/C/F/TAF arm and 
increased in the control arm (Fig. 3). Over 48 weeks, esti-
mated glomerular filtration rate (based on serum cysta-
tin C) remained generally stable with D/C/F/TAF across 
these demographic subgroups (see Additional file 1: Fig-
ure S1). Median changes in lipid values from baseline to 
week 48 were also generally similar across demographic 
subgroups in the D/C/F/TAF arm, and across subgroups 
in the control arm (see Additional file 1: Figure S2).
In the bone investigation substudy, increases in BMD 
over time in the hip, lumbar spine, and femoral neck 
were observed with D/C/F/TAF across subgroups based 
on age, gender, and race (Fig. 4 and see Additional file 1: 
Figure S3). There were no fractures unrelated to trauma 
in any arm across subgroups [5].
Discussion
EMERALD allowed treatment-experienced, virologically 
suppressed patients with varied treatment histories to 
enroll, and thus switching from a bPI + emtricitabine/
TDF to D/C/F/TAF was evaluated in a population more 
reflective of the real world than other recent switch 
studies [6–8]. In the current analysis of EMERALD, low 
rates of virologic rebound and high virologic response 
rates were observed regardless of demographic char-
acteristics, prior treatment experience (including prior 
VF), and ARV regimen at baseline in patients who 
switched to D/C/F/TAF compared with continuing on 
their baseline regimen. Efficacy results with D/C/F/TAF 
were generally similar to other recent switch studies 
[6–8], although direct comparisons are difficult due to 
differences in inclusion criteria and the resulting study 
populations.
No resistance to any D/C/F/TAF component was 
observed in EMERALD, which is consistent with the 
established high barrier to resistance of darunavir [2]. 
This result is important because among virologically sup-
pressed patients, resistance mutations may be archived 
and thus have the potential to reemerge at the time of 
virologic rebound. Reemergent resistance is a particu-
lar concern among individuals with prior VF. In EMER-
ALD, plasma samples were taken at baseline for potential 




Fig. 1 Virologic rebound rates through week 48 by subgroup. D/C/F/TAF darunavir/cobicistat/emtricitabine/tenofovir alafenamide,  
ARV antiretroviral, VF virologic failure, bPI boosted protease inhibitor, CI confidence interval. *Differences (95% CI) in virologic rebound rate between 
treatment arms are reported above the brackets. The total number of patients in each treatment arm for each subgroup is reported below the x‑axis 
labels. †For patients ≤ 50 years without polypharmacy, virologic rebound rates were 2.5% (11/436) with D/C/F/TAF and 2.9% (6/206) with control; 
for patients > 50 years with polypharmacy, these rates were 0% (0/108) with D/C/F/TAF and 2.0% (1/50) with control. ‡Data are not reported for 
the 1 patient who had used 3 prior ARVs. §Darunavir with ritonavir or cobicistat, atazanavir with ritonavir or cobicistat, and lopinavir with ritonavir. 
¶Ritonavir with darunavir, atazanavir, or lopinavir; and cobicistat with darunavir or atazanavir
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future exploratory research, and genoarchive analysis 
of these samples has been performed for patients who 
rebounded and those with prior VF [10].
D/C/F/TAF was associated with a favorable safety 
and tolerability profile in the overall EMERALD popu-
lation and across all subgroups. Improved renal func-
tion and bone safety were observed with D/C/F/TAF 
compared with control in the overall population over 
48  weeks [5], consistent with the switch from TDF to 
TAF in this arm [11–13], and results were generally 
similar regardless of age, gender, or race. Furthermore, 
changes in lipid parameter values through week 48 did 
not vary by demographic characteristics and, as previ-
ously described [5], low proportions of patients initi-
ated lipid-lowering therapy during the study, with no 
significant differences between treatment arms. The 
higher proportion of patients with ≥ 1 study drug-
related AE among those who switched to D/C/F/TAF, 
compared with those who continued their current 
regimen in the control arm, has been observed in prior 
switch studies [14].
Accelerated aging has been associated with HIV-1 
infection, and polypharmacy and aging-related comor-
bidities, such as osteopenia/osteoporosis and increased 
bone fracture risk, are clinical concerns [15–18]. There-
fore, evaluation of safety parameters for different age 
groups is important in studies of new HIV-1 treatment 
regimens. In the current analysis of EMERALD, among 
patients > 50  years with polypharmacy in the D/C/F/TAF 
arm, none discontinued due to a related AE (and none 
experienced virologic rebound). Overall, the bone 
safety profile of D/C/F/TAF was generally consistent 
in patients ≤ 50 and > 50  years at week 48. Bone safety 
results with D/C/F/TAF were also consistent in women 
and men after 48  weeks, which was reassuring given 
that women may experience an increased risk of bone 
events, particularly after menopause [19, 20]. There 
were few fractures in the overall population and, more 
importantly, all reported fractures were trauma-related 
[5].
A limitation of this study was the smaller number 
of patients in some of the subgroups who are histori-
cally underrepresented in clinical trials (e.g., > 50 years, 
women, black/African American) [21]. Neverthe-
less, the overall findings from this analysis show that 
switching to D/C/F/TAF may be an option for a broad 
range of virologically suppressed patients with HIV-1, 
in particular those who are experienced with multiple 
ARV agents and/or have had prior VF, as well as those 
currently on multi-tablet regimens of lopinavir, ataza-
navir, or darunavir. Moreover, the consistent results 
regardless of bPI used at baseline, together with the 
advantages of darunavir compared with other PIs [3, 
22], suggest that D/C/F/TAF, the only PI-based STR, is 
a viable treatment choice for virologically suppressed 
patients currently on a PI-based regimen.
(See figure on next page.)
Fig. 2 Virologic response and VF rates at week 48 by subgroup. VF virologic failure, D/C/F/TAF darunavir/cobicistat/emtricitabine/tenofovir 
alafenamide, ARV antiretroviral, bPI boosted protease inhibitor, CI confidence interval, FDA Food and Drug Administration. *Differences  
(95% CI) in virologic response rate between treatment arms are reported above the brackets. The total number of patients in each treatment arm 
for each subgroup is reported below the x‑axis labels. †For each subgroup, patients with missing virologic data (per FDA snapshot) in the D/C/F/TAF 
and control arms, respectively, were as follows: 4% and 6% for those ≤ 50 years, 6% and 6% for those > 50 years, 4% and 6% for men,  
5% and 6% for women, 4% and 7% for those who are non‑black/African American, and 7% and 4% for those who are black/African American. ‡For 
patients ≤ 50 years without polypharmacy, rates of HIV‑1 RNA < 50 copies/mL were 96% (419/436) with D/C/F/TAF and 94% (193/206) with control; 
for patients > 50 years with polypharmacy, these rates were 93% (100/108) with D/C/F/TAF and 92% (46/50) with control. §For each subgroup, 
patients with missing virologic data (per FDA snapshot) in the D/C/F/TAF and control arms, respectively, were as follows: 3.5% and 3.1% of those 
who used 4 prior ARVs, 5.1% and 8.9% of those who used 5 prior ARVs, 4.3% and 3.3% of those who used 6 prior ARVs, 4.3% and 10.0% of those who 
used 7 prior ARVs, 5.2% and 7.9% of those who used > 7 prior ARVs, 4.6% and 5.5% of those with 0 prior VFs, and 2.6% and 7.5% of those with  
≥ 1 prior VF. ¶Data are not reported for the 1 patient who used 3 prior ARVs. #For each subgroup, patients with missing virologic data (per FDA 
snapshot) in the D/C/F/TAF and control arms, respectively, were as follows: 3% and 5% for the darunavir group, 7% and 8% for the atazanavir or 
lopinavir group, 4% and 7% for the ritonavir group, 4% and 2% for the cobicistat group. **Darunavir with ritonavir or cobicistat, atazanavir with 
ritonavir or cobicistat, and lopinavir with ritonavir. ††Ritonavir with darunavir, atazanavir, or lopinavir; and cobicistat with darunavir or atazanavir








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig. 3 Changes from baseline to week 48 in renal laboratory parameters based on demographic characteristics. D/C/F/TAF darunavir/cobicistat/
emtricitabine/tenofovir alafenamide, SE standard error, RBP retinol binding protein. *The total number of patients in each treatment arm for each 
subgroup is reported at the bottom of the figure
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Conclusions
Switching to D/C/F/TAF may be an effective strategy for 
individuals who are stably suppressed and would like to 
simplify therapy, including patients with prior experience 
with multiple ARVs or a history of prior VF (without a 
history of darunavir RAMs or VF on a darunavir-based 
regimen).
Additional file
Additional file 1: Table S1 Baseline demographic and disease character‑
istics. Table S2. Summary of AEs week 48 by prior treatment experience. 
Table S3. Summary of AEs through week 48 by ARV regimen at baseline. 
Figure S1. Mean change in  eGFRcystC from baseline to week 48. Figure S2. 
Lipid values at baseline and week 48 by demographic subgroups. Figure 
S3. Changes from baseline in femoral neck BMD over time based on 
demographic characteristics.
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Fig. 4 Changes from baseline in BMD over time (hip and lumbar spine) based on demographic characteristics. BMD bone mineral density, D/C/F/TAF 
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the legends
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